ESLAW
MaterialsEstrella Immunopharma Inc - Warrants (29/09/2028)
$0.10-0.02 (-14.60%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ESLAW Today?
No stock-specific AI insight has been generated for ESLAW yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$221,500
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding2.2M
ESLAW News
10 articles- Estrella Immunopharma to Participate in the D. Boral Capital Global ConferenceYahoo Finance·May 5, 2026
- Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap ResearchYahoo Finance·Mar 23, 2026
- ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-TYahoo Finance·Mar 18, 2026
- Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either?Barchart·Nov 4, 2025
- Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable PatientsYahoo Finance·Nov 3, 2025
- Estrella Immunopharma Regains Compliance with Nasdaq Listing RequirementsYahoo Finance·Oct 6, 2025
- Is Estrella Immunopharma (NASDAQ:ESLA) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Aug 14, 2025
- Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaYahoo Finance·Jun 5, 2025
- Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity FinancingYahoo Finance·Jun 3, 2025
- Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s LymphomasYahoo Finance·May 29, 2025
All 10 articles loaded
Price Data
Open$0.00
Previous Close$0.10
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$221,500
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding2.2M
About Estrella Immunopharma Inc - Warrants (29/09/2028)
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
Listed October 2, 2023
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—